Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Risk management needed for nano medical technology, says senior devices expert

This article was originally published in Clinica

Executive Summary

A comprehensive and systematic risk management-based approach, rather than a prescriptive regulatory approach, is essential for the future development and success of nano-and other novel medical technologies both from the point of view of promoting innovation and of safeguarding public health. That is the view of Richard Moore, manager, nanomedicine and life sciences, at Europe's major nanotechnology information centre, the Institute of Nanotechnology (IoN), based in Scotland. Mr Moore, has only recently joined the IoN, after working as director of science and innovation at the European medtech industry association, Eucomed, for nearly 10 years. He was previously with the European Committee for Standardisation as project manager, healthcare, for six years before taking up the Eucomed job, and told Clinica that he is "glad that he can offer his expertise in medical nanotechnology to the institute". He sees many challenges ahead in this field where technological progress is leaping ahead, with regulation struggling to keep up. Understanding the real risks associated with these products is proving complex.

You may also be interested in...



GT Medical Technologies Raised $16M In Funding To Expand Brain Tumor Therapy

The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.

AMS Acquires Raleigh Adhesive Coatings Company For £22M ($29M) In Cash

Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business. 

Amgen Hands Omecamtiv Back To Cytokinetics

While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.

Topics

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel